Related references
Note: Only part of the references are listed.New criteria for response assessment: role of minimal residual disease in multiple myeloma
Bruno Paiva et al.
BLOOD (2015)
Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction
Andy C. Rawstron et al.
BLOOD (2015)
The Use of MAGE C1 and Flow Cytometry to Determine the Malignant Cell Type in Multiple Myeloma
Kirsty Wienand et al.
PLOS ONE (2015)
Monitoring M-Proteins in Patients with Multiple Myeloma Using Heavy-Chain Variable Region Clonotypic Peptides and LC-MS/MS
David R. Barnidge et al.
JOURNAL OF PROTEOME RESEARCH (2014)
Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry
N. Puig et al.
LEUKEMIA (2014)
Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study
Andy C. Rawstron et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
IMWG consensus on maintenance therapy in multiple myeloma
Heinz Ludwig et al.
BLOOD (2012)
Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes
Simone Ferrero et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management
S. Vincent Rajkumar
AMERICAN JOURNAL OF HEMATOLOGY (2011)
Combined Submyeloablative and Myeloablative Dose Intense Melphalan Results in Satisfactory Responses with Acceptable Toxicity in Patients with Multiple Myeloma
Nicolas Novitzky et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
How to do successful gene expression analysis using real-time PCR
Stefaan Derveaux et al.
METHODS (2010)
Flow Cytometric Immunophenotyping and Minimal Residual Disease Analysis in Multiple Myeloma
Ritu Gupta et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2009)
The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments
Stephen A. Bustin et al.
CLINICAL CHEMISTRY (2009)
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
R. A. Kyle et al.
LEUKEMIA (2009)
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
Bruno Paiva et al.
BLOOD (2008)
Monitoring of minimal residual disease in multiple myeloma after allo-SCT:: flow cytometry vs PCR-based techniques
M. Lioznov et al.
BONE MARROW TRANSPLANTATION (2008)
MAGE-C1/CT-7 expression in plasma cell myeloma: Sub-cellular localization impacts on clinical outcome
M. Tinguely et al.
CANCER SCIENCE (2008)
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders
Andy C. Rawstron et al.
HAEMATOLOGICA (2008)
Rituximab monotherapy is highly effective in splenic marginal zone lymphoma
C. Kalpadakis et al.
HEMATOLOGICAL ONCOLOGY (2007)
International uniform response criteria for multiple myeloma
B. G. M. Durie et al.
LEUKEMIA (2006)
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors:: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
Timothy Hughes et al.
BLOOD (2006)
The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation
AA Jungbluth et al.
BLOOD (2005)
Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program
E Beillard et al.
LEUKEMIA (2003)
Minimal residual disease monitoring in multiple myeloma
FE Davies et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2002)
Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method
KJ Livak et al.
METHODS (2001)
Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: Results of a multicenter randomized controlled trial
AK Stewart et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
